Technology ❯ Biotechnology

mRNA Technology

Vaccine Development Vaccine Technology Drug Development Vaccine Innovation Vaccine Production Cancer Research Research and Development Pharmaceutical Technology Vaccine Delivery Therapeutics Clinical Trials Cancer Therapy Personalized Medicine mRNA-1083 Cancer Vaccines Artificial Intelligence Drug Delivery Systems Innovations

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Investors weigh promising Phase 2b results against the need for Phase 3 confirmation and a cautious analyst outlook.

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

US Cuts $500 Million in mRNA Vaccine Research Funding

Membrane-Bound mRNA HIV Vaccine Elicits Neutralizing Antibodies in 80% of Participants

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy